Clinical trials: Pruritis
Pain, Postoperative, Postoperative Nausea and Vomiting
Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery
There will be two groups in this study: one group will be given the standard infusion of naloxone, a drug which helps reduce side effects from opioids needed after surgery, and the other group will receive a higher dose.
- Conditions
- Pain, Postoperative, Postoperative Nausea and Vomiting, Scoliosis
- Trial name
- NCT01531439
- Testing
- Naloxone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Children's Mercy Hospital Kansas City
Tinea Pedis
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
- Trial name
- NAFT-600 (NCT01290341)
- Testing
- NAFT-600 (naftin 2 % gel)
- Where
- 23 sites in United States
- Volunteers
- 860 people
- Sponsor
- Merz North America, Inc.
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Hepatic Impairment
Study of Nalbuphine ER in Participants With Hepatic Impairment
This research study will evaluate the effect of hepatic impairment on the pharmacokinetics (the breakdown of the drug in the body) of parallel-group, multiple oral doses nalbuphine extended release (NAL ER), tablets in people…
- Trial name
- NCT04020016
- Testing
- Nalbuphine ER
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Trevi Therapeutics
Pruritus, Chronic Urticaria
Safety Study of Levocetirizine and Fexofenadine
This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.
- Conditions
- Pruritus, Chronic Urticaria, Allergic Rhinitis
- Trial name
- LAWAF (NCT01586091)
- Testing
- Levocetirizine Oral Tablet, Fexofenadine 60 Mg Oral Tablet
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Tinea Pedis
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing solution footbath and it's effect on the clinical signs and symptoms associated with Tinea Pedis
- Trial name
- NCT02871011
- Testing
- Nitric Oxide, Water
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nitric Solutions Inc.
Alagille Syndrome
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and…
- Trial name
- ITCH (NCT02057692)
- Testing
- LUM001
- Where
- 13 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in…
- Trial name
- REMIX-1 (NCT05030311)
- Testing
- LOU064 25 mg (b.i.d), LOU064 25 mg (b.i.d) as a tablet.
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a…
- Trial name
- NCT01110330
- Testing
- Ketoconazole 2% cream (formulation F012) (Nizoral), Ketoconazole 2% cream (formulation F126)
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 583 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Eczema, Allergy Symptoms
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who…
- Conditions
- Eczema, Allergy Symptoms, Psoriasis, Itch
- Trial name
- NCT02075632
- Testing
- Alclometasone dipropionate cream
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Chronic Pruritus
Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone
The purpose of this study is to assess the efficacy and safety of sublingual naloxone in the treatment of chronic itch in patients under arsenic exposure.
- Trial name
- NCT03751111
- Testing
- Naloxone
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Xiangya Hospital of Central South University
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
- Trial name
- NCT03489941
- Testing
- EM-100, Zaditor®, Vehicle
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Bausch & Lomb Incorporated
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
- Trial name
- NCT06262607
- Testing
- CLE-400, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Clexio Biosciences Ltd.
Uremic Pruritus
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
- Trial name
- NCT05885737
- Testing
- Difelikefalin Injection
- Where
- 35 sites in China
- Volunteers
- 260 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Atopic Dermatitis
Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
The objective of this 1 week trial is to evaluate the efficacy of an over-the-counter (OTC) 1% colloidal oatmeal skin protectant cream in adults and children with mild to moderate AD.
- Trial name
- NCT02691507
- Testing
- EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Prurigo Nodularis, Nodularis Prurigo
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to…
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Trial name
- NCT02174419
- Testing
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- Trevi Therapeutics
Atopic Dermatitis
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
- Trial name
- NCT02651714
- Testing
- Tradipitant
- Where
- 28 sites in United States
- Volunteers
- 168 people
- Sponsor
- Vanda Pharmaceuticals
Perennial Allergic Rhinitis, Rhinitis, Allergic
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explored the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers.
- Trial name
- NCT05122143
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Altamira Medica Ltd.
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer